AN2 Therapeutics, Inc.
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its proprietary boron chemistry platform. The company trades on the Nasdaq Global Select Market under the ticker symbol AN2. More information about the company is… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What AN2 Therapeutics, Inc. does
In the company’s own words
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its proprietary boron chemistry platform. The company trades on the Nasdaq Global Select Market under the ticker symbol AN2. More information about the company is available at www.an2therapeutics.com.
The company's development pipeline spans three therapeutic areas: hematologic diseases, infectious diseases, and oncology. Its lead program, epetraborole, is an oral small-molecule therapeutic in Phase 2 development for polycythemia vera, a blood cancer characterized by overproduction of red blood cells, with an estimated 155,000 affected patients in the United States. The company is also advancing epetraborole through a Phase 2 investigator-initiated study for Mycobacterium abscessus complex lung disease, a serious non-tuberculous mycobacterial infection with limited treatment options and high mortality rates.
AN2's second clinical-stage candidate, AN2-502998, entered Phase 1 testing in 2025 for Chagas disease, an infectious disease affecting an estimated six to ten million people worldwide. The company's research pipeline includes two preclinical oncology programs targeting PI3Kα and ENPP1, with plans to advance both into development in 2026. The company also maintains global health programs focused on melioidosis and tuberculosis, funded primarily through non-dilutive grant funding from government agencies and foundations.
The company does not operate manufacturing facilities and relies on third-party contract manufacturers for all raw materials, drug substance, and finished drug product. AN2 holds exclusive worldwide licenses to epetraborole and related compounds through agreements with Anacor Pharmaceuticals and maintains regional licensing arrangements with Brii Biosciences for China, Hong Kong, Taiwan, and Macau. The company's intellectual property portfolio consists entirely of in-licensed patents and patent applications, with patent coverage for epetraborole expected to extend through 2046 in certain jurisdictions without patent term extensions.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- MENLO PARK, CA
- Fiscal year end
- December
- CIK
- 1880438
- SIC
- 2834
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns AN2 Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · AN2 Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do AN2 Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of AN2 Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in AN2 Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”